Compare iShares International Treasury Bond ETF (IGOV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Pfizer Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Pfizer Inc trades at $27.81 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 122× iShares International Treasury Bond ETF's market cap, and Pfizer Inc pays a 6.18% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Pfizer Inc for 158 Days on average.
| IGOV | PFE | |
|---|---|---|
Market Cap | $1.30B | $158.56B |
Volume | 693,740 | 44,138,282 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $29.02 |
52-Week Low | $39.65 | $23.67 |
Typical Hold Time | 92 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.70, down 0.48% with a bearish technical outlook as moving averages signal selling pressure. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. Recent news highlights rising global bond yields, which may impact interest-rate sensitive sectors. The stock shows neutral oscillator signals with RSI levels near oversold territory at 30-37.
Investment outlook remains cautious due to incomplete financial data and bearish technical indicators. Rising Treasury yields pose macroeconomic headwinds, while the absence of valuation metrics complicates risk-reward analysis. Investors require updated SEC filings and earnings reports to properly evaluate the company's financial health and growth prospects.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
